defenseworld.net
Botanix Pharmaceuticals Q2 Earnings Call Highlights
Botanix Pharmaceuticals (ASX: BOT) executives used a quarterly investor call held during the company's 2026 U.S. national sales meeting to highlight early commercial traction for its hyperhidrosis drug Sofdra, improving revenue trends, and efforts to strengthen manufacturing economics. The update covered the period ending 31 December 2025 and included discussion of the company's Quarterly Activity Report